FEB 0 2 2005 S

PATENT
Attorney Docket No. 401232

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

CHIKAMI et al.

Art Unit: 1616

Application No. 09/857,963

Examiner: K. George

Filed: August 2, 2001

For:

METHODS FOR PRODUCING A COATED BIOLOGICALLY ACTIVE

PARTICLE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents U.S. Patent and Trademark Office Randolph Building 401 Dulany Street, Customer Window, Mail Stop Alexandria, VA 22314

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

In re Appln. of CHIKAMI et al. Application No. 09/857,963

The In	formation Disclosure Statement is being filed:
	within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
\boxtimes	after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes <i>one</i> of:
	the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).
	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
	after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).
	after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.
Copie	s of the References
	Copies of the references listed on the enclosed Form 1449 are enclosed herewith.
\boxtimes	Copies of U.S. patents that are listed on the accompanying Form 1449 are not enclosed herewith. Copies of other references identified on the accompanying Form 1449 are enclosed herewith.
	Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3)

	cation No. 09/857,96							
	A copy of the foreign search report is enclosed herewith. The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the							
	references were pre	viously furnished are set	out below:					
	U.S. APPLIC		S1	atus (check o	ne)			
	S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED			
1.			`					
2.								
3.								
State	ment under 37 CFR	1.97(e)						
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.							
	The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.							
State	ment under 37 CFR	1.704(d)						
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.							
Fees								
	No fee is owed by the IDS Fee of \$18	he applicant(s). 80 under 37 CFR 1.17(p)						

Method of Payment of Fees Attached is a check in the amount of \$ Charge Deposit Account No. 12-1216 in the amount of \$180. (A duplicate copy of this communication is enclosed for that purpose.) **Authorization to Charge Additional Fees** \boxtimes If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.) Instructions as to Overpayment Credit Account No. 12-1216.

Respectfully submitted,

Shannon Schemel, Reg. No. 47,926 LEYDIG, VOIT & MAYER 700 Thirteenth Street, N.W., Suite 300 Washington, DC 20005-3960 (202) 737-6770 (telephone) (202) 737-6776 (facsimile)

Date: February 2, 2005

In re Appln. of CHIKAMI et al. Application No. 09/857,963

Refund

SDS:ves

	/ 0	6 0
Please type a plus sign (+) inside this box	FEB 0	2 2005
	V. C.	

•			17.	S/		
TE TRADENA					Complete if Known	
Substitute for form 1449A/B/PTO		Application Number	09/857,963			
INEC	DRMATION I	חפר	OSLIDE	Filing Date	August 2, 2201	
	-			First Named Inventor	CHIKAMI	
STATEMENT BY APPLICANT				Group Art Unit	1616	
	(Use as many sheet	s as nec	essary)	Examiner Name	K. George	
Sheet	1	of	1	Attorney Docket Number	401232	

			U.	S. PATENT DOCUMENTS				
Examiner Initials	Doc. No.	U.S. Patent Document Application or Kind Patent Number Code					Date of Publication	Filing Date If Appropriate
	D 1	4,583,985		Preiseggir	4/22/86			
	D2	4,612,364		Yamamoto et al.	9/16/86			
	D3	4,851,226		Julian et al.	7/25/89			
	D4	5,176,734		Fujita et al.	1/5/93			
	D5	2003/0157247		Chikami et al.	8/21/03			
			ļ					
						·		
			l					

				FOREIGI	N PATENT DOCUMENTS			
Foreign Patent Document							Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
	D6	JP	50-44176		Kuri Kagaku Sochi KK (Abstract)	4/21/75		
	D7	JP	63-162593		Asahi Chem Ind Co Ltd (Abstract)	7/6/88		
	D8	JP	42-2079		Ube Ind Ltd (Abstract)	7/22/92		
	D9	JP	57-126402		Asahi Kasei Kogyo KK (Abstract)	8/6/92		
	D10	JP	60-9303		Ube Ind Ltd (Abstract)	1/18/94		

	OTHER - NON PATENT LITERATURE DOCUMENTS								
Examiner		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item							
Initials	Doc. No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*+					

Examiner Signature	Date Considered	·	

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).